CRISPR Therapeutics AG
CRSP
$54.13
-$0.19-0.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 3.12% | -97.58% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.12% | -97.58% | |||
| Cost of Revenue | -11.50% | 58.23% | |||
| Gross Profit | 11.60% | -177.91% | |||
| SG&A Expenses | -1.97% | 6.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.27% | 48.87% | |||
| Operating Income | 10.34% | -129.80% | |||
| Income Before Tax | -53.65% | -268.43% | |||
| Income Tax Expenses | 16.50% | 58.43% | |||
| Earnings from Continuing Operations | -53.35% | -264.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -53.35% | -264.49% | |||
| EBIT | 10.34% | -129.80% | |||
| EBITDA | 10.62% | -140.50% | |||
| EPS Basic | -51.36% | -262.46% | |||
| Normalized Basic EPS | 18.78% | -266.45% | |||
| EPS Diluted | -51.66% | -262.46% | |||
| Normalized Diluted EPS | 18.78% | -266.45% | |||
| Average Basic Shares Outstanding | 1.32% | 0.56% | |||
| Average Diluted Shares Outstanding | 1.32% | 0.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||